Ensovibep, a SARS-CoV-2 antiviral DARPin, is safe and well tolerated in healthy volunteers: results of a first-in-human, ascending single-dose Phase 1 study.
Nina StojchevaStacy GladmanMarianne SoergelChristof ZittRoxana DrakeTony LockettCarine MarchandPierre FustierVaia StavropoulouElena FernandezNathana Lopes PettigianiKate WatkinsAdeep PuriRandall WatsonPhilippe LegenneMichael StumppMalcolm BoycePublished in: British journal of clinical pharmacology (2023)
Ensovibep proved safe in this first-in-human safety study and exhibited pharmacokinetic and pharmacodynamic parameters consistent with the expected treatment period required for acute COVID-19 infection.